Physician profile
Wingtat Mui
NPI 1497837090
$16,644.54
in general payments reported to CMS, 2019-2025
28 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,297 · 2020: $1,112 · 2021: $2,253 · 2022: $2,377 · 2023: $2,276 · 2024: $2,808 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,599 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,599.20 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,169.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Gilead Sciences, INC. | $2,665.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,069.84 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $1,283.06 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,063.74 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $1,027.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $858.81 | 2019-2025 | |
| Amgen INC. | $811.12 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $547.37 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $507.82 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Janssen Pharmaceuticals, INC | $459.60 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $386.68 | 2019-2024 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $373.27 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $260.02 | 2019-2025 | Zoryve |
| Pfizer INC. | $230.62 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $175.95 | 2022-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $172.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $140.39 | 2019-2020 | |
| Viiv Healthcare Company | $107.28 | 2024-2025 | Apretude |
| Corium, LLC | $71.88 | 2023 | Adlarity |
| E.R. Squibb & Sons, L.L.C. | $61.69 | 2019 | |
| Seqirus USA INC | $49.10 | 2021-2025 | Fluad, Flucelvax |
| Ironwood Pharmaceuticals, INC | $43.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.68 | 2024 | Voquezna |
| Mannkind Corporation | $17.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.32 | 2021 | |
| Horizon Therapeutics Plc | $15.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wingtat Mui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.